Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

• Association of SNGC expression with overall survival [ Designated as safety issue: No ]
  

• Association of SNGC expression with progression-free survival [ Designated as safety issue: No ]
  
• Association of SNGC expression with clinical covariates [ Designated as safety issue: No ]
  
• Association of SNCG expression with other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, ... [ Designated as safety issue: No ]
  
• Association between SNCG expression and synchronous or metachronous breast cancers [ Designated as safety issue: No ]
  

OBJECTIVES:

Primary

• Determine whether synuclein-γ (SNCG) expression in primary tumor is associated with overall survival (OS) in uterine papillary serous carcinoma (UPSC) patients.

Secondary

• Determine whether SNCG expression is associated with clinical covariates (age at diagnosis, race, surgical stage, depth of myometrial invasion, presence of lymph vascular space invasion, lymph node status, location of extrauterine disease, chemotherapy, and radiation therapy) in UPSC patients.
• Determine whether SNCG expression is associated with other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 in primary tumor tissue.
• Determine whether SNCG expression is associated with progression-free survival (PFS).
• Determine whether SNCG expression is associated with synchronous or metachronous breast cancers.
• Determine whether SNCG can be detected in sera from UPSC patients. (Exploratory)
• Determine whether serum SNCG in UPSC patients differs from that in normal healthy control women and women with endometrioid endometrial cancer. (Exploratory)
• Determine whether serum SNCG in UPSC patients is associated with overall survival (OS), clinical covariates (listed above), tumor expression of biomarkers (listed above), PFS, and synchronous or metachronous breast cancers. (Exploratory)
• Develop prediction models with a panel of biomarkers and clinical prognostic factors for OS, PFS, and synchronous or metachronous breast cancers in UPSC patients. (Exploratory)

OUTLINE: Archived serum and tumor tissue samples are analyzed for synuclein-γ (SNCG) expression and other biomarker expression, including TP53 (p53), HER-2, folate receptor alpha (FOLR1), estrogen receptor (ER), progesterone receptor (PR), phosphatase and tensin homolog (PTEN), phosphorylated AKT (pAKT), pERK, and p16 by microarray analysis, IHC assays, and western blot. Results are then compared with patients' existing clinical, demographic, and pathology data, including history of breast cancer (metachronous) or breast cancer diagnosed at the same time as the endometrial cancer (synchronous).